» Articles » PMID: 30092289

Jakinibs for the Treatment of Immune Dysregulation in Patients with Gain-of-function Signal Transducer and Activator of Transcription 1 (STAT1) or STAT3 Mutations

Citing Articles

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency.

Roppelt A, Markina U, Beloglazova I, Parshin V, Kanner D, Pershin D Front Immunol. 2025; 15:1523256.

PMID: 39959585 PMC: 11825476. DOI: 10.3389/fimmu.2024.1523256.


Infections in Inborn Errors of STATs.

Wang C, Freeman A Pathogens. 2024; 13(11).

PMID: 39599507 PMC: 11597637. DOI: 10.3390/pathogens13110955.


ASIA Syndrome: State-of-the-Art and Future Perspectives.

Caldarelli M, Rio P, Giambra V, Gasbarrini A, Gambassi G, Cianci R Vaccines (Basel). 2024; 12(10).

PMID: 39460349 PMC: 11511404. DOI: 10.3390/vaccines12101183.


Novel germline STAT3 gain-of-function mutation causes autoimmune diseases and severe growth failure.

Saito K, Fujimoto M, Funajima E, Serada S, Ohkawara T, Ishihara M J Allergy Clin Immunol Glob. 2024; 3(4):100312.

PMID: 39253104 PMC: 11381862. DOI: 10.1016/j.jacig.2024.100312.


JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review.

Atschekzei F, Traidl S, Carlens J, Schutz K, von Hardenberg S, Elsayed A Front Immunol. 2024; 15:1400348.

PMID: 39247195 PMC: 11377292. DOI: 10.3389/fimmu.2024.1400348.


References
1.
Vargas-Hernandez A, Mace E, Zimmerman O, Zerbe C, Freeman A, Rosenzweig S . Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2017; 141(6):2142-2155.e5. PMC: 5924437. DOI: 10.1016/j.jaci.2017.08.040. View

2.
Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen P, Rumi E . A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2013; 120(4):513-20. PMC: 4231215. DOI: 10.1002/cncr.28441. View

3.
Weinacht K, Charbonnier L, Alroqi F, Plant A, Qiao Q, Wu H . Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017; 139(5):1629-1640.e2. PMC: 5482293. DOI: 10.1016/j.jaci.2016.11.022. View

4.
Higgins E, Al Shehri T, McAleer M, Conlon N, Feighery C, Lilic D . Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015; 135(2):551-3. DOI: 10.1016/j.jaci.2014.12.1867. View

5.
Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Becerra J . Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016; 127(25):3154-64. PMC: 4920021. DOI: 10.1182/blood-2015-11-679902. View